High rate of adverse drug reactions with a novel tuberculosis re-treatment regimen combining triple doses of both isoniazid and rifampicin

High rate of adverse drug reactions with a novel tuberculosis re-treatment regimen combining triple doses of both isoniazid and rifampicin

Objectives: High-dose rifampicin (R) and isoniazid (H) are known to be safe but were not yet combined in a single regimen. The primary objective of the TRIple-DOse RE-treatment (TRIDORE) study is to determine whether a 6-month firstline regimen with triple dose of both R and H (intervention arm; 6R3...

Full description

Bibliographic Details
Main Authors: Mahamadou Bassirou Souleymane, Sani Kadri, Alberto Piubello, Achilleas Tsoumanis, Alphazazi Soumana, Hamidou Issa, Abdoulaziz Kabirou Amoussa, Armand Van Deun, Lutgarde Lynen, Bouke Catherine de Jong, Tom Decroo
Format: Article
Language:English
Published: Elsevier 2023-08-01
Series:International Journal of Infectious Diseases
Subjects:
High rifampicin
High isoniazid
Adverse drug reactions
Online Access:http://www.sciencedirect.com/science/article/pii/S1201971223005507

Internet

http://www.sciencedirect.com/science/article/pii/S1201971223005507

Similar Items